Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | Blinatumomab’s place in the ALL treatment landscape

Ryan Cassaday • 20 Jun 2022
EHA 2022
Acute Lymphoblastic Leukemia Leukemia Antibodies Blinatumomab Dasatinib Ponatinib

Ryan Cassaday, MD, University of Washington, Seattle, WA, discusses blinatumomab’s place in the acute lymphoblastic leukemia (ALL) treatment landscape, highlighting its role in relapsed/refractory (R/R) disease, its future in the frontline setting, and the promise of combinations with other agents, including dasatinib and ponatinib. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Disclosures

Research funding from Amgen, Kite/Gilead, Merck, Pfizer, Servier, and Vanda Pharmaceuticals; consulting/honoraria from Amgen, Kite/Gilead, and Pfizer; and spouse is employed by and owns stock in Seagen.

More from Ryan Cassaday

The future of immunotherapy for the treatment of ALL
2:39
The future of immunotherapy for the treatment of ALL
Ryan Cassaday • 20 Jun 2022
Results from a subgroup analysis of ZUMA-3 and the efficacy of brexu-cel in R/R B-ALL
2:48
Results from a subgroup analysis of ZUMA-3 and the efficacy of brexu-cel in R/R B-ALL
Ryan Cassaday • 20 Jun 2022
Dose-adjusted EPOCH plus inotuzumab ozogamicin for B-ALL
3:01
Dose-adjusted EPOCH plus inotuzumab ozogamicin for B-ALL
Ryan Cassaday • 20 Jun 2022
Improving the SOC for ALL with inotuzumab
2:31
Improving the SOC for ALL with inotuzumab
Ryan Cassaday • 1 Jun 2018

Related Videos

Unmet needs in CLL genomics: heterogeneity and clinical impact
1:11
Unmet needs in CLL genomics: heterogeneity and clinical impact
Elias Campo • 16 Oct 2026
Insights into key topics most likely to impact day-to-day CLL management
1:40
Insights into key topics most likely to impact day-to-day CLL management
Alessandra Ferrajoli • 16 Oct 2026
Translating current CLL evidence into national guidelines: which gaps remain?
3:33
Translating current CLL evidence into national guidelines: which gaps remain?
Mary Ann Anderson • 16 Oct 2026
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
2:40
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
Philip Thompson • 22 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals